Physician profile
Thomas A Hansbrough
NPI 1285623561
$2,060.79
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $105 · 2021: $481 · 2022: $573 · 2023: $512 · 2024: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $489.59 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Optinose US, INC. | $408.95 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $402.82 | 2021-2024 | Dupixent |
| Genzyme Corporation | $312.37 | 2021-2024 | |
| Alk-Abello, INC | $80.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $72.24 | 2019-2021 | |
| Abbvie INC. | $59.56 | 2021-2023 | |
| Phadia US INC. | $36.89 | 2020-2024 | Immunocap |
| Arbor Pharmaceuticals, INC. | $36.21 | 2019 | |
| Pfizer INC. | $30.69 | 2023 | |
| Kaleo, INC. | $28.39 | 2019-2020 | |
| Smith+Nephew, INC. | $22.47 | 2019 | |
| Stryker Corporation | $21.97 | 2021 | |
| Intersect Ent, INC. | $16.40 | 2019 | |
| Medtronic, INC. | $15.83 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $13.13 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hansbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.